Huiyu Pharma

Huiyu Pharma is a leading Chinese pharmaceutical company focused on the development and global commercialization of oncology and vascular treatments. Founded in 2010 and headquartered in Sichuan, the company has achieved significant success in international markets, particularly in Europe, where it was a pioneer in exporting Chinese-made oncology injectables. Huiyu operates a dual-track strategy, maintaining a strong portfolio of high-end generic drugs while aggressively expanding its innovative pipeline, which includes monoclonal antibodies, bispecifics, and antibody-drug conjugates (ADCs). The company is listed on the Shanghai Stock Exchange's STAR Market and operates large-scale, EU-GMP compliant manufacturing facilities. With a presence in over 90 countries, Huiyu Pharma is committed to improving patient access to high-quality, affordable medicines worldwide.